细胞染色体P450 2C19基因型和克洛皮多格雷尔在缺血性中风患者中:非随机临床试验
Yo Han Jung1,2, Tae-Jin Song3,4, Jinkwon Kim5
1Department of Neurology, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Republic of Korea.
JAMA network open
|April 4, 2025
概括
患有CYP2C19功能丧失 (LOF) 基因组的患者在用克洛皮多格雷尔治疗时,在缺血性中风后患有心血管事件的风险更高. 基因定型可以为中风患者的治疗决策提供信息.
科学领域:
- 药物基因组学 药物基因组学
- 神经学 神经学
- 心脏病学 心脏病学
背景情况:
- 细胞染色体P450 2C19 (CYP2C19) 基因型影响了克洛皮多格雷尔的抗血小板功效.
- 有限的前性数据存在于CYP2C19对克洛皮多格雷尔在预防急性缺血性中风患者心血管事件的有效性的影响.
研究的目的:
- 研究用克洛皮多格雷尔治疗急性缺血性中风患者的CYP2C19基因型和临床结果之间的关联.
主要方法:
- 一项前性非随机临床试验,涉及2910名在急性缺血性中风后72小时内接受克洛皮多格雷尔治疗的患者.
- 患者的基因型为CYP2C19功能丧失 (LOF) 的等位基因.
- 主要结局:6个月内发生心血管事件;安全结局:严重出血和全因死亡率.
主要成果:
- 携带CYP2C19 LOF等位基因的携带者与非携带者相比,心血管事件的发生率更高 (2.7%对1.6%,P=.048).
- 两组之间没有观察到重大出血或所有原因死亡率的显著差异.
结论:
- 当用克洛皮多格雷尔治疗时,CYP2C19 LOF等位基因携带者在急性缺血性中风后患心血管事件的风险增加.
- 对CYP2C19的基因定型可能有助于在中风患者中个性化抗血小板治疗.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
422
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
422
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
52
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
52
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.1K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.1K
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
34
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
34
Drug Metabolism: Phase I Reactions
2.9K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
2.9K


